- Home
- FORR vs ELDN Comparison
FORR vs ELDN Comparison
Compare FORR & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORR
- ELDN
- Stock Information
- Founded
- FORR 1983
- ELDN 2004
- Country
- FORR United States
- ELDN United States
- Employees
- FORR N/A
- ELDN N/A
- Industry
- FORR Diversified Commercial Services
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- FORR Consumer Discretionary
- ELDN Health Care
- Exchange
- FORR Nasdaq
- ELDN Nasdaq
- Market Cap
- FORR 193.5M
- ELDN 178.4M
- IPO Year
- FORR 1996
- ELDN N/A
- Fundamental
- Price
- FORR $10.53
- ELDN $3.11
- Analyst Decision
- FORR
- ELDN Strong Buy
- Analyst Count
- FORR 0
- ELDN 2
- Target Price
- FORR N/A
- ELDN $12.50
- AVG Volume (30 Days)
- FORR 73.4K
- ELDN 639.8K
- Earning Date
- FORR 07-29-2025
- ELDN 08-18-2025
- Dividend Yield
- FORR N/A
- ELDN N/A
- EPS Growth
- FORR N/A
- ELDN N/A
- EPS
- FORR N/A
- ELDN N/A
- Revenue
- FORR $422,269,000.00
- ELDN N/A
- Revenue This Year
- FORR N/A
- ELDN N/A
- Revenue Next Year
- FORR $2.04
- ELDN N/A
- P/E Ratio
- FORR N/A
- ELDN N/A
- Revenue Growth
- FORR N/A
- ELDN N/A
- 52 Week Low
- FORR $8.50
- ELDN $2.30
- 52 Week High
- FORR $20.62
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- FORR 56.84
- ELDN 60.47
- Support Level
- FORR $9.46
- ELDN $2.60
- Resistance Level
- FORR $9.93
- ELDN $3.16
- Average True Range (ATR)
- FORR 0.43
- ELDN 0.18
- MACD
- FORR 0.09
- ELDN 0.05
- Stochastic Oscillator
- FORR 72.83
- ELDN 91.07
About FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.